Glaukos Corporation specializes in ophthalmic pharmaceuticals and medical technologies, focusing on innovative therapies for glaucoma, corneal disorders, and retinal diseases. The company develops microinvasive devices to lower intraocular pressure and offers various drug delivery systems, including transdermal pharmaceuticals and sustained-release implants, aimed at enhancing patient vision and managing ocular conditions.